What biosimilars have been approved in the United States?
Is there a list of all biosimilars approved in the United States?
There have been 74 biosimilars approved by the U.S. Food and Drug Administration (FDA). The most recent biosimilar approval was Jobevne (bevacizumab-nwgd) on April 9, 2025.
What is a Biosimilar?
According the to FDA, a biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from an existing FDA-approved reference product.
Biological products are a diverse category of products, and include therapeutic proteins (example filgrastim) and monoclonal antibodies (example adalimumab). Biological products are generally large, complex molecules, and inherent variations are normal and expected within the manufacturing process.
A manufacturer developing a biosimilar will need to demonstrate that its product is highly similar to the characteristics of the reference product in terms of purity, chemical identity, and bioactivity. The manufacturer must also demonstrate that its product has no clinically meaningful differences to the reference product in terms of safety, purity, and potency (safety and effectiveness) which is determined though human pharmacokinetic and pharmacodynamic studies, and additional clinical studies if needed.
Biosimilar products can only be dispensed in place of another biological product if the health care provider specifically prescribes the biosimilar product by name.
What is an Interchangeable?
An interchangeable product is a biological product that meets all the requirements for a biosimilar product, but also meets additional requirements outlined by the Biologics Price Competition and Innovation Act.
A manufacturer developing an interchangeable product will need to demonstrate that its product is expected to produce the same clinical result as the reference product in any given patient. If a product is to be administered to a patient more than once, the risk in terms of safety and reduced efficacy of switching back and forth between an interchangeable product and a reference product will need to have been evaluated.
Interchangeable products may be substituted at pharmacy-level without the intervention of the health care provider who prescribed the reference product. A health care provider also can prescribe an interchangeable product just like they would prescribe a biosimilar or a reference product. (Note that pharmacy laws and practices vary from state to state.)
Learn about cost-savings, clinical use, and safety of biosimilars.
Biosimilars by reference product (or by approval date)
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Avtozma (tocilizumab-anoh) |
Interchangeable (certain strengths) | Celltrion, Inc. | January 24, 2025 |
|
Tyenne (tocilizumab-aazg) |
Biosimilar | Fresenius Kabi USA, LLC | March 5, 2024 |
|
Tofidence (tocilizumab-bavi) |
Biosimilar | Biogen Inc. | September 29, 2023 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Jobevne (bevacizumab-nwgd) |
Biosimilar | Biocon Biologics Ltd. | April 9, 2025 |
|
Avzivi (bevacizumab-tnjn) |
Biosimilar | Bio-Thera Solutions, Ltd. | December 6, 2023 |
|
Vegzelma (bevacizumab-adcd) |
Biosimilar | Celltrion, Inc. | September 27, 2022 |
|
Alymsys (bevacizumab-maly) |
Biosimilar | Amneal Pharmaceuticals, Inc. | April 13, 2022 |
|
Zirabev (bevacizumab-bvzr) |
Biosimilar | Pfizer Inc. | June 27, 2019 |
|
Mvasi (bevacizumab-awwb) |
Biosimilar | Amgen Inc. | September 14, 2017 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Eticovo (etanercept-ykro) |
Biosimilar | Samsung Bioepis Co., Ltd. | April 25, 2019 |
|
Erelzi (etanercept-szzs) |
Biosimilar | Sandoz Inc. | August 30, 2016 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Retacrit (epoetin alfa-epbx) |
Biosimilar | Hospira Inc. | May 15, 2018 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Pavblu (aflibercept-ayyh) |
Biosimilar | Amgen, Inc. | August 23, 2024 |
|
Enzeevu (aflibercept-abzv) |
Biosimilar | Sandoz Inc. | August 9, 2024 |
|
Ahzantive (aflibercept-mrbb) |
Biosimilar | Formycon AG | June 28, 2024 |
|
Opuviz (aflibercept-yszy) |
Interchangeable | Samsung Bioepis Co., Ltd. | May 20, 2024 |
|
Yesafili (aflibercept-jbvf) |
Interchangeable | Biocon Biologics Inc. | May 20, 2024 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Hercessi (trastuzumab-strf) |
Biosimilar | Accord BioPharma Inc. | April 26, 2024 |
|
Kanjinti (trastuzumab-anns) |
Biosimilar | Amgen Inc. | June 13, 2019 |
|
Trazimera (trastuzumab-qyyp) |
Biosimilar | Pfizer Inc. | March 11, 2019 |
|
Ontruzant (trastuzumab-dttb) |
Biosimilar | Samsung Bioepis Co., Ltd. | January 18, 2019 |
|
Herzuma (trastuzumab-pkrb) |
Biosimilar | Celltrion, Inc. | December 14, 2018 |
|
Ogivri (trastuzumab-dkst) |
Biosimilar | Mylan GmbH | December 1, 2017 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Simlandi (adalimumab-ryvk) |
Interchangeable (certain strengths) | Alvotech and Teva Pharmaceutical Industries Ltd. | February 23, 2024 |
|
Yuflyma (adalimumab-aaty) |
Biosimilar | Celltrion, Inc. | May 23, 2023 |
|
Idacio (adalimumab-aacf) |
Biosimilar | Fresenius Kabi USA, LLC | December 13, 2022 |
|
Yusimry (adalimumab-aqvh) |
Biosimilar | Coherus BioSciences, Inc. | December 17, 2021 |
|
Hulio (adalimumab-fkjp) |
Interchangeable | Mylan Pharmaceuticals Inc. | July 6, 2020 |
|
Abrilada (adalimumab-afzb) |
Interchangeable | Pfizer Inc. | November 15, 2019 |
|
Hadlima (adalimumab-bwwd) |
Interchangeable (certain strengths) | Samsung Bioepis Co., Ltd. | July 23, 2019 |
|
Hyrimoz (adalimumab-adaz) |
Interchangeable (certain strengths) | Sandoz Inc. | October 30, 2018 |
|
Cyltezo (adalimumab-adbm) |
Interchangeable (certain strengths) | Boehringer Ingelheim Pharmaceuticals, Inc. | August 25, 2017 |
|
Amjevita (adalimumab-atto) |
Interchangeable (certain strengths) | Amgen Inc. | September 23, 2016 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Rezvoglar (insulin glargine-aglr) |
Interchangeable | Eli Lilly and Company | December 17, 2021 |
|
Semglee (insulin glargine-yfgn) |
Interchangeable | Mylan Pharmaceuticals Inc. | July 28, 2021 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Cimerli (ranibizumab-eqrn) |
Interchangeable | Coherus BioSciences, Inc. | August 2, 2022 |
|
Byooviz (ranibizumab-nuna) |
Interchangeable | Samsung Bioepis Co., Ltd. | September 17, 2021 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Stimufend (pegfilgrastim-fpgk) |
Biosimilar | Fresenius Kabi USA, LLC | September 1, 2022 |
|
Fylnetra (pegfilgrastim-pbbk) |
Biosimilar | Amneal Pharmaceuticals, Inc. | May 26, 2022 |
|
Nyvepria (pegfilgrastim-apgf) |
Biosimilar | Pfizer Inc. | June 10, 2020 |
|
Ziextenzo (pegfilgrastim-bmez) |
Biosimilar | Sandoz Inc. | November 4, 2019 |
|
Udenyca (pegfilgrastim-cbqv) |
Biosimilar | Coherus BioSciences, Inc. | November 2, 2018 |
|
Fulphila (pegfilgrastim-jmdb) |
Biosimilar | Mylan N.V. | June 4, 2018 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Nypozi (filgrastim-txid) |
Biosimilar | Tanvex BioPharma USA, Inc. | June 28, 2024 |
|
Releuko (filgrastim-ayow) |
Biosimilar | Kashiv BioSciences, LLC | February 25, 2022 |
|
Nivestym (filgrastim-aafi) |
Biosimilar | Pfizer Inc. | July 20, 2018 |
|
Zarxio (filgrastim-sndz) |
Biosimilar | Sandoz Inc. | March 6, 2015 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Merilog (insulin aspart-szjj) |
Biosimilar | Sanofi-Aventis U.S. LLC | February 14, 2025 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Conexxence (denosumab-bnht) |
Biosimilar | Fresenius Kabi USA, LLC | March 25, 2025 |
|
Stoboclo (denosumab-bmwo) |
Biosimilar | Celltrion, Inc. | February 28, 2025 |
|
Ospomyv (denosumab-dssb) |
Biosimilar | Samsung Bioepis Co., Ltd. | February 13, 2025 |
|
Jubbonti (denosumab-bbdz) |
Interchangeable | Sandoz Inc. | March 5, 2024 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Avsola (infliximab-axxq) |
Biosimilar | Amgen Inc. | December 6, 2019 |
|
Ixifi (infliximab-qbtx) |
Biosimilar | Pfizer Inc. | December 13, 2017 |
|
Renflexis (infliximab-abda) |
Biosimilar | Samsung Bioepis Co., Ltd. | April 21, 2017 |
|
Inflectra (infliximab-dyyb) |
Biosimilar | Celltrion, Inc. | April 5, 2016 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Riabni (rituximab-arrx) |
Biosimilar | Amgen Inc. | December 17, 2020 |
|
Ruxience (rituximab-pvvr) |
Biosimilar | Pfizer Inc. | July 23, 2019 |
|
Truxima (rituximab-abbs) |
Biosimilar | Celltrion, Inc. | November 28, 2018 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Epysqli (eculizumab-aagh) |
Biosimilar | Samsung Bioepis Co., Ltd. | July 19, 2024 |
|
Bkemv (eculizumab-aeeb) |
Interchangeable | Amgen Inc. | May 28, 2024 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Steqeyma (ustekinumab-stba) |
Biosimilar | Celltrion, Inc. | December 17, 2024 |
|
Yesintek (ustekinumab-kfce) |
Biosimilar | Biocon Biologics Ltd. | November 29, 2024 |
|
Imuldosa (ustekinumab-srlf) |
Biosimilar | Accord BioPharma, Inc. | October 10, 2024 |
|
Otulfi (ustekinumab-aauz) |
Biosimilar | Fresenius Kabi and Formycon AG | September 27, 2024 |
|
Pyzchiva (ustekinumab-ttwe) |
Biosimilar | Sandoz and Samsung Bioepis Co., Ltd. | June 28, 2024 |
|
Selarsdi (ustekinumab-aekn) |
Biosimilar | Alvotech and Teva Pharmaceutical Industries Ltd. | April 16, 2024 |
|
Wezlana (ustekinumab-auub) |
Interchangeable (certain strengths) | Amgen Inc. | October 31, 2023 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Tyruko (natalizumab-sztn) |
Biosimilar | Sandoz Inc. | August 24, 2023 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Bomyntra (denosumab-bnht) |
Biosimilar | Fresenius Kabi USA, LLC | March 25, 2025 |
|
Osenvelt (denosumab-bmwo) |
Biosimilar | Celltrion, Inc. | February 28, 2025 |
|
Xbryk (denosumab-dssb) |
Biosimilar | Samsung Bioepis Co., Ltd. | February 13, 2025 |
|
Wyost (denosumab-bbdz) |
Interchangeable | Sandoz Inc. | March 5, 2024 |
| Name | Regulatory Designation | Company Name | FDA Approved |
|---|---|---|---|
|
Omlyclo (omalizumab-igec) |
Interchangeable | Celltrion, Inc. | March 7, 2025 |
Related questions
- What are the most common skin conditions? (with photos)
- What are monoclonal antibodies?
- Is Xolair an immunosuppressant?
Biosimilars by approval date
- Jobevne (bevacizumab-nwgd) - April 9, 2025
- Bomyntra (denosumab-bnht) - March 25, 2025
- Conexxence (denosumab-bnht) - March 25, 2025
- Omlyclo (omalizumab-igec) - March 7, 2025
- Osenvelt (denosumab-bmwo) - February 28, 2025
- Stoboclo (denosumab-bmwo) - February 28, 2025
- Merilog (insulin aspart-szjj) - February 14, 2025
- Xbryk (denosumab-dssb) - February 13, 2025
- Ospomyv (denosumab-dssb) - February 13, 2025
- Avtozma (tocilizumab-anoh) - January 24, 2025
- Steqeyma (ustekinumab-stba) - December 17, 2024
- Yesintek (ustekinumab-kfce) - November 29, 2024
- Imuldosa (ustekinumab-srlf) - October 10, 2024
- Otulfi (ustekinumab-aauz) - September 27, 2024
- Pavblu (aflibercept-ayyh) - August 23, 2024
- Enzeevu (aflibercept-abzv) - August 9, 2024
- Epysqli (eculizumab-aagh) - July 19, 2024
- Ahzantive (aflibercept-mrbb) - June 28, 2024
- Pyzchiva (ustekinumab-ttwe) - June 28, 2024
- Nypozi (filgrastim-txid) - June 28, 2024
- Bkemv (eculizumab-aeeb) - May 28, 2024
- Yesafili (aflibercept-jbvf) - May 20, 2024
- Opuviz (aflibercept-yszy) - May 20, 2024
- Hercessi (trastuzumab-strf) - April 25, 2024
- Selarsdi (ustekinumab-aekn) - April 16, 2024
- Tyenne (tocilizumab-aazg) - March 5, 2024
- Jubbonti (denosumab-bbdz) - March 5, 2024
- Wyost (denosumab-bbdz) - March 5, 2024
- Simlandi (adalimumab-ryvk) - February 23, 2024
- Avzivi (bevacizumab-tnjn) - December 6, 2023
- Wezlana (ustekinumab-auub) - October 31, 2023
- Tofidence (tocilizumab-bavi) - September 29, 2023
- Tyruko (natalizumab-sztn) - August 24, 2023
- Yuflyma (adalimumab-aaty) - May 23, 2023
- Idacio (adalimumab-aacf) - December 13, 2022
- Vegzelma (bevacizumab-adcd) - September 27, 2022
- Stimufend (pegfilgrastim-fpgk) - September 1, 2022
- Cimerli (ranibizumab-eqrn) - August 2, 2022
- Fylnetra (pegfilgrastim-pbbk) - May 26, 2022
- Alymsys (bevacizumab-maly) - April 13, 2022
- Releuko (filgrastim-ayow) - February 25, 2022
- Yusimry (adalimumab-aqvh) - December 17, 2021
- Rezvoglar (insulin glargine-aglr) - December 17, 2021
- Byooviz (ranibizumab-nuna) - September 17, 2021
- Semglee (insulin glargine-yfgn) - July 28, 2021
- Riabni (rituximab-arrx) - December 17, 2020
- Hulio (adalimumab-fkjp) - July 6, 2020
- Nyvepria (pegfilgrastim-apgf) - June 10, 2020
- Avsola (infliximab-axxq) - December 6, 2019
- Abrilada (adalimumab-afzb) - November 15, 2019
- Ziextenzo (pegfilgrastim-bmez) - November 4, 2019
- Hadlima (adalimumab-bwwd) - July 23, 2019
- Ruxience (rituximab-pvvr) - July 23, 2019
- Zirabev (bevacizumab-bvzr) - June 27, 2019
- Kanjinti (trastuzumab-anns) - June 13, 2019
- Eticovo (etanercept-ykro) - April 25, 2019
- Trazimera (trastuzumab-qyyp) - March 11, 2019
- Ontruzant (trastuzumab-dttb) - January 18, 2019
- Herzuma (trastuzumab-pkrb) - December 14, 2018
- Truxima (rituximab-abbs) - November 28, 2018
- Udenyca (pegfilgrastim-cbqv) - November 2, 2018
- Hyrimoz (adalimumab-adaz) - October 30, 2018
- Nivestym (filgrastim-aafi) - July 20, 2018
- Fulphila (pegfilgrastim-jmdb) - June 4, 2018
- Retacrit (epoetin alfa-epbx) - May 15, 2018
- Ixifi (infliximab-qbtx) - December 13, 2017
- Ogivri (trastuzumab-dkst) - December 1, 2017
- Mvasi (bevacizumab-awwb) - September 14, 2017
- Cyltezo (adalimumab-adbm) - August 25, 2017
- Renflexis (infliximab-abda) - April 21, 2017
- Amjevita (adalimumab-atto) - September 23, 2016
- Erelzi (etanercept-szzs) - August 30, 2016
- Inflectra (infliximab-dyyb) - April 5, 2016
- Zarxio (filgrastim-sndz) - March 6, 2015
Read next
How long before Xolair starts working?
Free serum IgE levels are decreased within an hour of Xolair administration. However it may take several months for the full effects of Xolair to be seen, although some symptom improvement may be noted after a few weeks. Significant improvements were noted after 4 months in those with allergic asthma, after 3 months in those with chronic urticaria, and after 16 to 20 weeks in those with Ig-E-mediated food allergies. Continue reading
Does Xolair cause hair loss?
Hair loss (alopecia), has been reported in Xolair clinical studies in at least 2% of people with chronic hives. Hair loss has also been noted in several case reports with Xolair. The hair loss effect appears to be transient, lasting from 3 to 4 months. Due to limited data, the exact cause of hair loss or how often it occurs is not known. Continue reading
Does Xolair cause cancer?
Xolair is associated with a slightly higher risk of cancer, but cancer specialists have determined that this does not mean that Xolair causes cancer. Research has shown that cancer occurred in 20 out of 4127 trial participants (0.5% of Xolair-treated study volunteers) and 5 out of 2236 (0.2%) of people who were assigned an inactive treatment. Continue reading
Related medical questions
- How does Xolair work?
- How long can Xolair stay out of the fridge?
- Xolair and Covid-19 vaccine, what should I know?
- Does Xolair cause weight gain?
- Can Xolair injection be used for allergies?
- Is Xolair a steroid?
- Can I take Xolair during pregnancy?
- Can Xolair be self-administered at home?
- What is Xolair approved for?
- Xolair Copay Card: Do I qualify, and how much can I save?
- What's the difference between Prolia and Reclast?
- Does Prolia weaken your immune system?
- How do you give a Prolia injection?
- Does Prolia cause weight gain?
- Does Prolia increase bone density?
- Evenity vs Prolia: Which is right for you?
- Xgeva vs Prolia. How do they compare?
- Can you drink alcohol while taking Prolia?
- How many years should you take Prolia?
- How long will the side effects of Prolia last?
- What medications are available to treat osteoporosis?
- Insights from a Pharmacist about Osteoporosis Treatments
- How can I prevent osteoporosis?
Related support groups
- Xolair (24 questions, 89 members)
- Prolia (45 questions, 222 members)
- Omalizumab (11 questions, 12 members)
- Insulin Aspart (5 questions, 6 members)
- Imuldosa (4 questions, 3 members)
- Conexxence (1 questions, 0 members)
- Osenvelt (1 questions, 3 members)
- Xbryk (1 questions, 3 members)
- Steqeyma (1 questions, 3 members)
- Stoboclo (1 questions, 3 members)
- Merilog (1 questions, 3 members)